Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Chenodeoxycholic Acid
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Chenodeoxycholic Acid is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Xanthomatosis, Cerebrotendinous.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
February 15, 2024
Lead Product(s) : Chenodeoxycholic Acid
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Cysteamine Hydrochloride
Therapeutic Area : Genetic Disease
Study Phase : Approved FDF
Sponsor : AllianceRx Walgreens
Deal Size : Undisclosed
Deal Type : Partnership
Details : As an exclusive partner, AllianceRx Walgreens Prime is able to offer end-to-end solutions for Leadiant Biosciences and Cystaran patients. Cystaran, a topical ophthalmic therapy for the treatment of corneal cystine crystals in patients with cystinosis.
Product Name : Cystaran
Product Type : Amino Acid
Upfront Cash : Undisclosed
March 22, 2022
Lead Product(s) : Cysteamine Hydrochloride
Therapeutic Area : Genetic Disease
Highest Development Status : Approved FDF
Sponsor : AllianceRx Walgreens
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : N-Acetyl-D-Mannosamine
Therapeutic Area : Neurology
Study Phase : Phase II
Sponsor : Brigham and Women's Hospital | National Human Genome Research Institute | National Institute of Neurological Disorders and Stroke | National Institute of Arthritis and Musculoskeletal and Skin Diseases | NeuroNext
Deal Size : Inapplicable
Deal Type : Inapplicable
Multi-Center Study of ManNAc for GNE Myopathy
Details : ManNAc is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Distal Myopathy, Nonaka Type.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
January 18, 2020
Lead Product(s) : N-Acetyl-D-Mannosamine
Therapeutic Area : Neurology
Highest Development Status : Phase II
Sponsor : Brigham and Women's Hospital | National Human Genome Research Institute | National Institute of Neurological Disorders and Stroke | National Institute of Arthritis and Musculoskeletal and Skin Diseases | NeuroNext
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : 131-I Tenatumomab
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Medpace, Inc
Deal Size : Inapplicable
Deal Type : Inapplicable
131Iodine-Tenatumomab Treatment in Tenascin-C Positive Cancer Patients
Details : 131-I Tenatumomab is a Radiolabeled Compounds drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Breast Neoplasms.
Product Name : Undisclosed
Product Type : Radiolabeled Compound
Upfront Cash : Inapplicable
November 11, 2015
Lead Product(s) : 131-I Tenatumomab
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Medpace, Inc
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Oxytocin
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Phase II
Recipient : Medical University of Vienna
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Oxytocin is a Hormone drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Sexual Dysfunction, Physiological.
Product Name : Undisclosed
Product Type : Hormone
Upfront Cash : Inapplicable
September 01, 2014
Lead Product(s) : Oxytocin
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Phase II
Recipient : Medical University of Vienna
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : DNR is a drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Precursor Cell Lymphoblastic Leukemia-Lymphoma.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
January 23, 2014
Lead Product(s) : Piperaquine Tetraphosphate
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Piperaquine Tetraphosphate is a Antibiotic drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Malaria, Falciparum.
Product Name : Undisclosed
Product Type : Antibiotic
Upfront Cash : Inapplicable
November 25, 2013
Lead Product(s) : Piperaquine Tetraphosphate
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : STP206
Therapeutic Area : Gastroenterology
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
STP206 for the Prevention of Necrotizing Enterocolitis (NEC)
Details : STP206 is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Enterocolitis, Necrotizing.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
October 01, 2013
Lead Product(s) : STP206
Therapeutic Area : Gastroenterology
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Peg L asparaginase
Therapeutic Area : Oncology
Study Phase : Phase I
Recipient : Dana-Farber Cancer Institute
Deal Size : Inapplicable
Deal Type : Inapplicable
A Pilot Study of Oncaspar® + Dexamethasone in Patients With Relapsed or Refractory T-Cell Lymphoma
Details : Pegaspargase is a Enzyme drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Lymphoma, T-Cell.
Product Name : Undisclosed
Product Type : Enzyme
Upfront Cash : Inapplicable
June 17, 2013
Lead Product(s) : Peg L asparaginase
Therapeutic Area : Oncology
Highest Development Status : Phase I
Recipient : Dana-Farber Cancer Institute
Deal Size : Inapplicable
Deal Type : Inapplicable
SST0001 (Roneparstat) in Advanced Multiple Myeloma
Details : Roneparstat is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Multiple Myeloma.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
January 10, 2013